Program Objectives

At the conclusion of this course, participants will be able to:

• identify the role of hydroxychloroquine in standard of care lupus management.
• describe the role of immunosuppressants and which ones to choose in SLE.
• list the barriers to proper care in lupus patients.
• differentiate the patients that my benefit from voclosporin and belimumab for lupus nephritis.
•  research new therapies in the pipeline and how they may benefit patients with SLE.

Target Audience
This course is intended for primary care physicians, internal medicine physicians, rheumatologists, nurse practitioners, physician assistants, residents in internal medicine, rheumatologist fellows, and other health care providers

 Topics:

*Note: these are continuous video recordings during the conference, they include individual lectures mentioned in the Detail section below

• 2023 Lupus brochure.pdf
• Deadliest Catch- a NETs story from SLE and APS to COVID-19.pdf
• Emerging Therapeutics in SLE.pdf
• How Does Diet Influence Systemic Lupus Erythematosus.pdf
• November 18 Full Live.mp4 (3 hours 30 minutes)
• Understanding Disparities in Systemic Lupus Erythematosus- Barriers and Opportunities for Improvement.pdf

*Detail:

• 8:30 Welcome and Announcements Hiroshi Kato, MD
• 8:35 How Does Diet Influence Systemic Lupus Erythematosus  Aaron Stubbs, MD
• 9:20 Deadliest Catch: a NETs story from SLE and APS to COVID-19 Ray Zuo, MD
• 10:05 Break
• 10:25 Understanding Disparities in Systemic Lupus Erythematosus: Barriers and Opportunities for Improvement Ashira Blazer, MD
• 11:10 Emerging Therapeutics in SLE Hiroshi Kato, MD
• 12:00 pm Course Adjourns